Please wait...

Learn

Finding accredited CPD

Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Description

While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.

This MJA narrative review shares more.

Details

Explain key components of the review.
List main recommendations.
Recognise changes in management as a result of the review.

Authors: Renata Libianto, Timothy ME Davis, Elif I Ekinci

Article Type: Narrative review

CPD Activity Details

Provider

Medical Journal of Australia

Domain

Educational Activities

Type

General Learning

Activity

Professional reading

CPD Hours

1h : 0m

Topic

Pharmaceutical Preparations, Cardiovascular Diseases, Endocrine System Diseases

Audience

Medical practitioners

Applicable CAPE Aspects

Effective Year

You have to log in to see the content of this module.

Provided by

Accredited by